- Home
- ALNY vs AEE Comparison
ALNY vs AEE Comparison
Compare ALNY & AEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALNY | AEE |
|---|---|---|
| Founded | 2002 | 1901 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 27.5B |
| IPO Year | 2004 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ALNY | AEE |
|---|---|---|
| Price | $224.00 | $104.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 17 |
| Target Price | ★ $370.55 | $116.81 |
| AVG Volume (30 Days) | 1.2M | ★ 1.9M |
| Earning Date | 10-29-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 2.88% |
| EPS Growth | ★ 206.88 | 21.04 |
| EPS | ★ 2.71 | 2.41 |
| Revenue | $1,037,418,000.00 | ★ $8,799,000,000.00 |
| Revenue This Year | $47.60 | $7.36 |
| Revenue Next Year | $26.59 | $6.38 |
| P/E Ratio | $82.59 | ★ $43.29 |
| Revenue Growth | ★ 22.88 | 15.43 |
| 52 Week Low | $197.81 | $96.57 |
| 52 Week High | $495.55 | $118.32 |
Technical Indicators
Market Signals| Indicator | ALNY | AEE |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 58.75 |
| Support Level | $219.54 | $101.57 |
| Resistance Level | $234.00 | $114.75 |
| Average True Range (ATR) | 8.80 | 1.38 |
| MACD | -1.30 | 0.74 |
| Stochastic Oscillator | 20.76 | 93.71 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About AEE Ameren Corporation
Ameren owns rate-regulated generation, transmission, and distribution networks that deliver electricity and natural gas through the company's two main subsidiaries, Ameren Missouri and Ameren Illinois. It serves 2.5 million electricity customers and 900,000 natural gas customers across its two service territories.